Regencell Bioscience Holdings Limited (RGC)

NASDAQ: RGC · Real-Time Price · USD

5.72

+0.10 (1.78%)

At close: Jul 24, 2026, 4:00 PM EDT

5.80

+0.08 (1.40%)

Pre-market: Jul 27, 2026, 4:00 AM EDT

RGC Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Selling, General & Admin	6.28	2.82	3.67	4.69	5.11	0.94
Research & Development	0.86	0.95	1.07	1.58	2.51	0.44
Total Operating Expenses	7.13	3.77	4.74	6.27	7.62	1.38
Operating Income	-7.13	-3.77	-4.74	-6.27	-7.62	-1.38
Total Non-Operating Income (Expense)	0.08	0.19	0.37	0.21	0.02	0.03
Pretax Income	-7.05	-3.58	-4.36	-6.06	-7.59	-1.35
Net Income	-7.05	-3.58	-4.36	-6.06	-7.59	-1.35
Minority Interest in Earnings	-	-	-0.06	-0.19	-0.15	-
Net Income to Common	-7.05	-3.58	-4.3	-5.87	-7.45	-1.35
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	494	494	494	494	487	380
Shares Outstanding (Diluted)	494	494	494	494	487	380
Shares Change (YoY)	-	-	-	1.62%	28.06%	-
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.02	-0.00
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.02	-0.00
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-4	-3.27	-4.01	-4.99	-6.05	-0.77
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.01	-0.00
EBITDA	-7.13	-3.38	-3.99	-5.5	-7.01	-1.35
EBIT	-7.13	-3.77	-4.74	-6.27	-7.62	-1.38

SEC Filings: 10-K · 10-Q